Silence Therapeutics (SLN) Share-based Compensation (2024 - 2026)

Silence Therapeutics has disclosed Share-based Compensation across 3 years of filings, most recently posting $2.4 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $2.4 million, down 30.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.0 million (down 55.62% YoY), and the FY2025 annual result was $8.1 million, down 50.49% from the prior year.
• Share-based Compensation came in at $2.4 million for Q1 2026 at Silence Therapeutics, up from -$86000.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $4.1 million in Q2 2024 to a low of -$86000.0 in Q4 2025.
• The 3-year median for Share-based Compensation is $3.5 million (2025), against an average of $3.0 million.
• Peak annual rise in Share-based Compensation reached 14.04% in 2025, while the deepest fall reached 102.16% in 2025.
• Silence Therapeutics' Share-based Compensation stood at $4.0 million in 2024, then sank by 102.16% to -$86000.0 in 2025, then jumped by 2945.35% to $2.4 million in 2026.
• The last three Share-based Compensation figures came in at $2.4 million (Q1 2026), -$86000.0 (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.